59293-18-4

Basic information

• Product Name: 2H-Pyran-4-carboxylicacid,tetrahydro-,hydrazide(9CI)
• Synonyms: 2H-Pyran-4-carboxylicacid,tetrahydro-,hydrazide(9CI);tetrahydro-2H-pyran-4-carbohydrazide(SALTDATA: FREE);4-Tetrahydropyrancarboxylic acid hydrazide;Tetrahydro-2H-pyran-4-carboxylic acid hydrazide;Oxane-4-carbohydrazide
• CAS NO: 59293-18-4
• Molecular Formula: C₆H₁₂N₂O₂
• Molecular Weight: 144.17
• Product Categories: AMIDE
• Mol File: 59293-18-4.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 342.5°C at 760 mmHg
• Flash Point: 161°C
• Appearance: /
• Density: 1.155g/cm³
• Vapor Pressure: 7.48E-05mmHg at 25°C
• Refractive Index: 1.494
• CAS DataBase Reference: 2H-Pyran-4-carboxylicacid,tetrahydro-,hydrazide(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 2H-Pyran-4-carboxylicacid,tetrahydro-,hydrazide(9CI)(59293-18-4)
• EPA Substance Registry System: 2H-Pyran-4-carboxylicacid,tetrahydro-,hydrazide(9CI)(59293-18-4)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 59293-18-4(Hazardous Substances Data)

Usage

General Description

2H-Pyran-4-carboxylic acid, tetrahydro-, hydrazide (9CI) is a chemical compound with the molecular formula C6H10N2O2. It is an organic compound that contains a pyran ring and a hydrazide functional group. 2H-Pyran-4-carboxylicacid,tetrahydro-,hydrazide(9CI) has potential applications in the field of medicinal chemistry and drug development due to its structural characteristics, which may make it suitable for use in the synthesis of biologically active compounds. Additionally, hydrazide derivatives have been studied for their biological activities, including antimicrobial, antiviral, and antitumor properties, which suggests that 2H-Pyran-4-carboxylic acid, tetrahydro-, hydrazide (9CI) may have similar potential pharmacological effects. Overall, this compound is of interest to researchers in the chemical and pharmaceutical industries for its potential applications in drug discovery and development.

InChI:InChI=1/C6H12N2O2/c7-8-6(9)5-1-3-10-4-2-5/h5H,1-4,7H2,(H,8,9)

Upstream product

• 110238-91-0 tetrahydropyran-4-carboxylic acid methyl ester 

Downstream Products

• 62909-49-3 2-bromo-4-(2-chloro-phenyl)-9-tetrahydropyran-4-yl-4H,6H-thieno[2,3-e][1,2,4]triazolo[3,4-c][1,4]oxazepine 

Relevant articles and documents

Exploration of diphenylalkyloxadiazoles as novel cardiac myosin activator

To explore novel cardiac myosin activator, a series of diphenylalkyl substituted 1,3,4-oxadiazoles and 1,2,4-oxadiazoles have been prepared and tested for cardiac myosin ATPase activation in vitro. In all cases, three carbon spacer between the oxadiazole core and one of the phenyl ring was considered crucial. In case of 1,3,4-oxadiazole, zero to two carbon spacer between oxadiazole core and other phenyl ring are favorable. Phenyl ring can be replaced by cyclohexyl moiety. In case of 1,2,4-oxadiazole, zero or one carbon spacer between the oxadiazole and other phenyl ring are favorable. Introduction of hydrogen bonding donor (NH) group at the 2nd position of the 1,3,4-oxadiazole enhances the activity. Substitutions on either of the phenyl rings or change of phenyl ring to other heterocycle are not tolerated for both the oxadiazoles. The prepared oxadiazoles showed selective activation for cardiac muscle over smooth and skeleton muscles.

DOPAMINE D3 RECEPTOR ANTAGONISTS COMPOUNDS

The disclosure is directed to novel dopamine D3 receptor antagonists, processes for their preparation, intermediates used in these processes, pharmaceutical compositions containing them and their use in therapy, including treating drug dependency and psychosis.

3- (1,2,4-TRIAZOL-3YLALKYL) AZABRICLO (3.1.0) HEXANE DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS

The present invention relates to novel compounds of formula (I) or pharmaceutically acceptable salt thereof: wherein " G is selected from a group consisting of: phenyl, pyridyl, benzothiazolyl and indazolyl; " p is an integer ranging from 0 to 5; " R1 is independently selected from a group consisting of: halogen, hydroxy, cyano, C1-4alkyl, haloC1-4alkyl, C1-4alkoxy, haloC1-4alkoxy, C1-4alkanoyl and SF5, or corresponds to a group R5; " each R2 is independently hydrogen, fluorine or C1-4alkyl; " n is 2, 3, 4, or 5; " R3 is C1-4alkyl; " R4 is hydrogen, or a C1-4alkyl group, a benzyl group, a phenyl group, a heterocyclyl group, a 5- or 6-membered heteroaromatic group, or a 8- to 11-membered bicyclic group, any of which groups is optionally substituted by 1, 2, 3 or 4 substituents selected from the group consisting of: halogen, cyano, C1-4alkyl, haloC1-4alkyl, C1-4alkoxy, haloC1-4alkoxy, C1-4alkanoyl and SF5;or R4 is a -SR6 group; " R5 is selected from a group consisting of: isoxazolyl, -CH2-N-pyrrolyl, 1,1-dioxido-2-isothiazolidinyl, thienyl, thiazolyl, pyridyl and 2-pyrrolidinonyl, and such a group is optionally substituted by one or two substituents selected from a group consisting of: halogen, cyano, C1-4alkyl, haloC1-4alkyl, C1-4alkoxy and C1-4alkanoyl; " R6 is C1-4alkyl or -CH2C3-4cycloalkyl; and when R1 is chlorine and p is 1, such R1 is not present in the ortho position with respect to the linking bond to the rest of the molecule; and when R1 corresponds to R5, p is 1. processes for their preparation, intermediates used in these processes, pharmaceutical compositions containing them and their use in therapy, as modulators of dopamine D3 receptors, e.g. to treat drug dependency, as antipsychotic agents, to treat obsessive compulsive spectrum disorders, premature ejaculation or cognition impairment.